New Personal Kinetigraph (PKG) Allows Parkinson’s Patients in the UK to Connect with their Specialists

  Although guidelines for Parkinson’s patients suggest that they visit a specialist every six months, according to a report in Parkinson’s News Today, the waiting period may be up to…

Continue Reading New Personal Kinetigraph (PKG) Allows Parkinson’s Patients in the UK to Connect with their Specialists
Latest Data Reinforces Effectiveness of a Potential Gene Therapy for Type 1 Spinal Muscular Atrophy
skeeze / Pixabay

Latest Data Reinforces Effectiveness of a Potential Gene Therapy for Type 1 Spinal Muscular Atrophy

According to a story from inpublic.globenewswire.com, the Novartis company AveXis has released interim data from an ongoing Phase 3 clinical trial of Zolgensma, a gene therapy drug that is being…

Continue Reading Latest Data Reinforces Effectiveness of a Potential Gene Therapy for Type 1 Spinal Muscular Atrophy
Possible Treatment for Marginal Zone Lymphoma Earns Orphan Drug Designation
GDJ / Pixabay

Possible Treatment for Marginal Zone Lymphoma Earns Orphan Drug Designation

According to a story from globenewswire.com, the biopharmaceutical company TG Therapeutics, Inc. recently made an announcement declaring that the US Food and Drug Administration (FDA) had awarded the company Orphan…

Continue Reading Possible Treatment for Marginal Zone Lymphoma Earns Orphan Drug Designation

Edible Antibodies Halt E. Coli in Pigs, Could Help End Overuse of Antibiotics

According to a publication at BioPortfolio, Belgian researchers are developing an orally-administered antibody medication for patients living with gastrointestinal disorders. In most cases, antibodies are injected into the bloodstream for…

Continue Reading Edible Antibodies Halt E. Coli in Pigs, Could Help End Overuse of Antibiotics
AMO Pharma Presents New Rating Scale for Type 1 Myotonic Dystrophy Symptoms
jarmoluk / Pixabay

AMO Pharma Presents New Rating Scale for Type 1 Myotonic Dystrophy Symptoms

A press release from American biopharmaceutical company AMO Pharma, published by PR Newswire, detailed the recent completion of the Company's new congenital myotonic dystrophy type 1 (CDM1) symptom-evaluation scale. The…

Continue Reading AMO Pharma Presents New Rating Scale for Type 1 Myotonic Dystrophy Symptoms
This Phenylketonuria Patient Helped Test a Breakthrough Therapy Only to Lose Access Once the Trial Ended
source: pixabay.com

This Phenylketonuria Patient Helped Test a Breakthrough Therapy Only to Lose Access Once the Trial Ended

According to a story from BBC, Louise Moorhouse gets the nutrition that she needs through two sources: pills and foul tasting nutrient shakes. This is because she was born with…

Continue Reading This Phenylketonuria Patient Helped Test a Breakthrough Therapy Only to Lose Access Once the Trial Ended

Artificial Intelligence(AI) and a Solution to Detect Familial Hypercholesterolemia

  Familial Hypercholesterolemia (FH) is often misdiagnosed as plain old high cholesterol because of overlapping symptoms such as elevated lipid levels. According to a recent article in MedicalView, FH is three…

Continue Reading Artificial Intelligence(AI) and a Solution to Detect Familial Hypercholesterolemia
Development of “Add-on” Therapy for Pulmonary Arterial Hypertension Ends After Poor Trial Showing
Fotorech / Pixabay

Development of “Add-on” Therapy for Pulmonary Arterial Hypertension Ends After Poor Trial Showing

According to a story from Pulmonary Hypertension News, the drug developer United Therapeutics recently issued a statement in which the company announced that it was ceasing the development of esuberaprost…

Continue Reading Development of “Add-on” Therapy for Pulmonary Arterial Hypertension Ends After Poor Trial Showing
Phase 3 Study Data Shows Obeticholic Acid Could Treat NASH-Linked Fibrosis
Source: Pixabay.com

Phase 3 Study Data Shows Obeticholic Acid Could Treat NASH-Linked Fibrosis

According to a press release from American biotechnology company Intercept Pharmaceuticals, the company recently released additional data supporting its phase 3 clinical trial of obeticholic acid (OCA) in the treatment…

Continue Reading Phase 3 Study Data Shows Obeticholic Acid Could Treat NASH-Linked Fibrosis
Company Announces Plans for Myotonic Dystrophy and Duchenne Muscular Dystrophy Treatments
rawpixel / Pixabay

Company Announces Plans for Myotonic Dystrophy and Duchenne Muscular Dystrophy Treatments

According to a story from CRWE World, the genetic medicines company Audentes Therapeutics has recently announced its intent to develop new therapies for myotonic dystrophy and Duchenne muscular dystrophy. These…

Continue Reading Company Announces Plans for Myotonic Dystrophy and Duchenne Muscular Dystrophy Treatments

Experimental Drug for HPV-Linked Recurrent Respiratory Papillomatosis Shows Early Promise

According to a press release from Inovio Pharmaceuticals, the American biotech company's experimental recurrent respiratory papillomatosis (RRP) drug INO-3106 showed promising results at the end of a pilot clinical study…

Continue Reading Experimental Drug for HPV-Linked Recurrent Respiratory Papillomatosis Shows Early Promise

Immunotherapy Drug to be Tested for Autoimmune Hepatitis and Primary Sclerosing Cholangitis

According to a story from finanzen.at, the biotechnology company Orbsen Therapeutics recently announced that its immunotherapy product ORBCEL-C is to be tested in a multi-site clinical trial called MERLIN that…

Continue Reading Immunotherapy Drug to be Tested for Autoimmune Hepatitis and Primary Sclerosing Cholangitis
Despite New Inflammatory Bowel Disease Therapies, Difficulty Treating Persists
source: pixabay.com

Despite New Inflammatory Bowel Disease Therapies, Difficulty Treating Persists

In a recent video interview with Healio, Dr. David Rubin recapped some of his discussion at the 2019 Interdisciplinary Autoimmune Summit. At the summit, he and his colleagues spoke about…

Continue Reading Despite New Inflammatory Bowel Disease Therapies, Difficulty Treating Persists
European Medicines Agency Okays Experimental Oral Mucositis Drug for Pediatric Investigation
Capri23auto / Pixabay

European Medicines Agency Okays Experimental Oral Mucositis Drug for Pediatric Investigation

According to a press release from American biotechnology company Soligenix, the European Medicines Agency's (EMA) Pediatric Committee recently agreed to the Company’s Pediatric Investigation Plan (PIP) for experimental oral mucositis…

Continue Reading European Medicines Agency Okays Experimental Oral Mucositis Drug for Pediatric Investigation